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Objective: To compare the efﬁcacy of in situ transforming growth factor-beta1 (TGF-b1)-pretreated
periosteum to untreated periosteum for regeneration of osteochondral tissue in rabbits.
Methods: In the pretreatment group, 12 month-old New Zealand white rabbits received subperiosteal
injections of 200 ng of TGF-b1 percutaneously in the medial side of the proximal tibia, 7 days prior to
surgery. Control rabbits received no treatment prior surgery. Osteochondral transverse defects measuring
5 mm proximal to distal and spanning the entire width of the patellar groove were created and repaired
with untreated or TGF-b1-pretreated periosteal grafts. Post-operatively the rabbits resumed normal cage
activity for 6 weeks.
Results: Complete ﬁlling of the defects with regenerated tissue was observed in both the TGF-b1-pre-
treated and control groups with reformation of the original contours of the patellar groove. The total
histological score (modiﬁed O’Driscoll) in the TGF-b1-pretreated group, 20 (95% Conﬁdence Interval (CI),
19e21), was signiﬁcantly higher (P¼ 0.0001) than the control group, 18 (16e19). The most notable
improvements were in structural integrity and subchondral bone regeneration. No signiﬁcant
differences in glycosaminoglycan or type II collagen content, or equilibrium modulus were found
between the surgical groups. The cambium of the periosteum regenerated at the graft harvest site was
signiﬁcantly thicker (P¼ 0.0065) in the TGF-b1-pretreated rabbits, 121 mm (94e149), compared to
controls, 74 mm (52e96), after 6 weeks.
Conclusions: This study demonstrates that in situ pretreatment of periosteum with TGF-b1 improves
osteochondral tissue regeneration at 6-weeks post-op compared to untreated periosteum in 12 month-
old rabbits.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
While tissue engineering and regenerativemedicine approaches
are very promising, their full potential has yet to be realized,
especially in the area of cartilage repair. In this pursuit, the use of
autologous cell sources such as cartilage, bone marrow, perichon-
drium, synovium, adipose, and periosteum have been explored1e8.
There are advantages and disadvantages associated with each of
these autologous sources, but the most efﬁcacious cell source forregory G. Reinholz, Cartilage
Clinic, 200 First Street SW,
Reinholz).
s Research Society International. Pdurable cartilage repair is yet to be determined. Ultimately,
randomized prospective clinical studies may provide a deﬁnitive
answer9. However, it is more likely that an individualized approach
to cartilage regeneration will be needed, which will require the
availability of multiple treatment options. Therefore, it is important
to continue to use preclinical models to investigate the optimal
conditions for cartilage regeneration with each available cell
source.
The clinical potential of conventional periosteal transplantation,
which is performed using an unaltered periosteal graft, has been
reported with varying results10e19. However, the regenerative
capacity of all periosteum is not equal. It is dependent on the
number of mesenchymal stem cells (MSCs) in the tissue which
varies depending on the graft donor site20, and the age of the
patient or laboratory animal21e24. This is likely to explain many ofublished by Elsevier Ltd. All rights reserved.
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attempts to optimize the regenerative capacity of periosteum prior
to tissue harvest have been reported25e28.
Previously, we reported the effect of age on cambium cellularity
and in vitro periosteal chondrogenesis in rabbits23. In that study, the
number of cambium cells and the amount of cartilage formed in
vitro from the periosteumwere signiﬁcantly decreased in 6, 12, and
24 month-old rabbits compared to 1.5e2 month-old rabbits23. We
subsequently demonstrated that it is possible to signiﬁcantly
increase the number of cambium cells and the amount of cartilage
formed in vitro from periosteum in 6, 12, and 24 month-old rabbits
using local subperiosteal injection of transforming growth factor-
beta1 (TGF-b1) with or without Insulin-like growth factor-I
(IGF-1)28. In that study, the effect of the growth factor injections
was dependent on the type of growth factor, the concentration and
the amount of time between injection and tissue harvest28. In 12
month-old rabbits, the greatest response was observed when
periosteumwas harvested 7 days after the injection of 200 ng TGF-
b1, which resulted in more than a 4-fold increase in cambium
cellularity and over a 2-fold increase in cartilage production in
vitro28. The values for cambium cellularity and cartilage yield after
200 ng TGF-b1 injection in 12 month-old rabbits were similar to
values previously obtained from rabbits between 2 and 4 months
old23,28. Therefore, in terms of the number of cambium cells present
and the ability of the periosteum to form cartilage, the periosteum
fromolder rabbits can be rejuvenated by local injection of TGF-b128.
In addition, subperiosteal TGF-b injection results in increased
extracellular matrix production and initiation of cartilage for-
mation28e30. Thus, after injection with TGF-b1, the periosteal graft
is primed for transplantation in vivo by increasing cell number and
initiating chondrogenesis prior to harvest.
Therefore, we hypothesized that in situ pretreatment of peri-
osteum with TGF-b1 would improve the outcome of periosteal
transplantation for osteochondral tissue regeneration. In this study,
we compared the efﬁcacy of TGF-b1-pretreated periosteal grafts vs
untreated control grafts to regenerate osteochondral tissue in the
patellar groove of 12 month-old rabbits using a previously estab-
lished model21,22.
Methods and materials
Study design
All work in this study was conducted with the approval of the
Mayo Clinic Institutional Animal Care and Use Committee. A total of
19 New Zealand white rabbits (12 months old) were used in this
study. The nine pretreated rabbits received subperiosteal injections
of TGF-b1 in themedial side of the left proximal tibia 7 days prior to
periosteal transplantation surgery. The 10 control rabbits receivedFig. 1. An osteochondral transverse defect, measuring 5 mm proximal to distal and spanning
jewelry saw. Measurements of all areas in the defects were done with a Vernier caliper. In co
with a 5 mm wide ﬁle and was approximately 2 mm below the surface of the middle of thno pretreatment prior to surgery. Osteochondral defects were
created and repaired based on a previously established model21,22.
In order to mimic the clinical approach, as previously described31,
the donor periosteal grafts were harvested from the same limb as
the recipient joint. After 6 weeks, the operated (left) and contra-
lateral control knees were harvested and cut in half along the
patellar groove. One half was processed for histology and analyzed
using a modiﬁed ÓDriscoll histological score22,32 and the Interna-
tional Cartilage Repair Society Score (ICRS) system33. The remaining
half underwent mechanical testing followed by biochemical anal-
yses for DNA content, collagen type II formation and glycosami-
noglycan (GAG) content.
In situ periosteal pretreatment
Seven days prior to surgery, rabbits in the pretreatment group
received subperiosteal injections of TGF-b1 as previously
described28. Brieﬂy, under general anesthesia, intravenous injec-
tion of acepromazine (0.75 mg/Kg), xylazine (5 mg/Kg), and ket-
amine (50 mg/Kg), the left legs of the rabbits were shaved and
prepared with surgical scrub. Four injections (10 ml) of 200 ng TGF-
b1 (R&D Systems, Inc., Minneapolis, MN) were then made percu-
taneously using a Hamilton syringe with a 30-gauge needle under
the periosteum of the medial proximal tibia. The injections were
standardized using the distal edge of the tibial tuberosity as
a landmark. The ﬁrst injection was always made 5 mm proximal to
the distal edge of the tibial tuberosity. The four injections were
distributed evenly within the 510 mm area of the medial prox-
imal tibia to be used as the periosteal graft harvest site in the
subsequent periosteal transplantation procedure.
Osteochondral defect
All operative procedures were performed under general anes-
thesia, which was induced by intravenous injection of aceproma-
zine (0.75 mg/Kg), xylazine (5 mg/Kg), and ketamine (50 mg/Kg).
With the rabbit in the supine position, one hind limb (left one) was
shaved from the hips to the ankles, prepared with Techni-care
scrub (Care-Tech Laboratories, Inc., St. Louis, MO), and draped.
The knee joint and the proximal tibiae were exposed by a 6 cm
anterior incision and the joint was opened by a 3 cm transvastus
approach, which allowed the patella to be dislocated laterally,
gaining full access to the patellar groove. An osteochondral trans-
verse defect, measuring 5 mm proximal to distal (Fig. 1), and
spanning the entire width of the patellar groove, as previously
described22,34, was created using a scalpel and a conventional
jewelry saw (Fig. 1). Measurements of all areas in the defects were
done with a Vernier caliper. In contrast to the original contour of
the patellar groove, the base of the defect was ﬂattened withthe entire width of the patellar groove, was created using a scalpel and a conventional
ntrast to the original contour of the patellar groove, the base of the defect was ﬂattened
e patellar groove.
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surface of themiddle of the patellar groove. The depth at themedial
and lateral edges was approximately 3e4 mm. A portable drill and
a 0.64 mm drill bit were used to make a hole in each corner of the
base of the defect and in the lateral and medial cortices adjacent to
the defect for ﬁxation of the periosteal graft as described below.
Periosteal transplantation
Using the same skin approach, the deep fascia overlying the
medial aspect of the proximal tibia was incised and retracted. In the
regions that were injected with TGF-b1, there was signiﬁcant
swelling and edema. In order to reach the plane of the periosteum,
the edematous tissue was ﬁrst removed. The distinct morphology
of this inﬂammatory tissue and the use of surgical loupes allowed
this to be done in a controlled manner without damaging the
underlying periosteum. Once exposed, a rectangular graft of peri-
osteum corresponding to the required size of the osteochondral
defect was elevated as previously described35. Control rabbits
received a periosteal graft that was not pretreated. The ﬁnal
thickness of the periosteal grafts were approximately 2 mm for the
TGF-b1-pretreated grafts and 1 mm for the control grafts as judged
by their position in the base of the osteochondral defects which
were 3 mm deep at their shallowest point. In both surgical groups,
the periosteal graft was placed on the base of the defect with the
cambium layer facing up into the joint and secured to the base of
the defect by passing a 4e0 Vicryl (polyglactin 910) suture through
the holes made in the corners of the defect. After having sutured
the ends of the graft on each side of the femur, the patella was
relocated. Hemostasis was obtained with a cautery coagulator, and
the joint was irrigated with normal saline prior to closing the
articular capsule. The arthrotomy and fascia-muscle wounds were
closed with single stitches of 4e0 Vicryl (polyglactin 910) suture
and single knots of 3e0 Vicryl suture respectively. Once the
arthrotomy was closed, passive ﬂexion and extension movements
were performed and patellar tracking was checked for lateral
dislocations or excessive tension that could alter the articulation
between the graft and the patellar joint surface. The remaining soft
tissue from the periosteal graft donor site was repaired using
a continuous locking 4e0 Vicryl suture. Inverted knots of 3e0
Vicryl suture were placed in the subcutaneous tissue to get a more
secure closing. The skin was closed with subcuticular 3e0 Vicryl
suture and the end knots were inverted and hidden under the skin.
The wound was cleaned with saline and spray bandage was applied
(Bard Protective Barrier Film, C.R. Bard, Inc., Convington, GA). To
alleviate post-operative pain, the rabbits received a single intra-
muscular injection of buprenorphine (0.1 mg/Kg). In order to avoid
wound infection and as a prophylaxis of pasteurella pneumonia
every animal received a single intramuscular injection of enro-
ﬂoxacin (Baytril) at 5 mg/Kg. After surgery rabbits were allowed
normal cage activity for 6 weeks. At the end of the experiment, the
rabbits were sacriﬁced by an overdose of intravenous sodium
pentobarbital.
Gross and histological analyses
The defect repair and corresponding contralateral sites were
documented by digital photography. The defect repair and contra-
lateral control sites were then excised. The osteochondral speci-
mens were cut in half sagittally along the center of the patellar
groove. Half of the specimens (divided equally between the medial
and lateral specimens) were prepared for histology while the other
half were analyzed mechanically and biochemically. The periosteal
graft harvest sites and underlying bone were also harvested for
histology. The specimens for histology were ﬁxed for 2 days in 10%formalin followed by 2 days in Bouin’s solution, decalciﬁed in 10%
ethylenediaminetetraacetic acid (EDTA), embedded in parafﬁn, and
sectioned at 5 mm. The osteochondral samples from the patellar
groovewere stained with safranin O/fast green. The periosteal graft
harvest site sampleswere stainedwith haematoxylin and eosin (H&
E). Three blinded observers scored the osteochondral samples using
the O’Driscoll score modiﬁed to include scores for the regenerated
bone tissue22,32 (Table I). A blinded observer histologically
measured the thickness of periosteum in the periosteal graft harvest
site samples using an automated system as reported previously28.
Brieﬂy, three sections were obtained from each tissue sample and
scanned at the periosteal harvest site using the Zeiss AuxioCamMRc
at the same magniﬁcation with the periosteal layer line horizontal
to the bottom edge of the scan’s frame of reference. The cambium
layerwas outlined byhand.Maximum thicknesswas determined by
comparing thicknesses in the outlined area from top to bottom.
Mechanical testing
Mechanical indentation testing was performed on the osteo-
chondral samples using a method similar to Duda et al.36. The
samples were placed, unconstrained, on a ﬂat dish with the carti-
lage surface perpendicular to the 1.6 mm cylindrical indenter.
Loading was applied at a rate of 5 N/min to a maximum force of 5 N
(maximum applied stress¼ 2.5 MPa). A Dynamic Mechanical
Analyzer (TA Instruments, New Castle, DE) was used to apply the
load. The 5 N load limit compressed the cartilage beyond the toe
region of the stressestrain curve. During testing the specimens
were immersed in saline. Applied stress was calculated by dividing
the applied force by the area of the indenter. Strain was deﬁned as
the indentation displacement divided by the original cartilage
thickness in the tested area. After the biomechanical testing,
cartilage was removed using a number 11 scalpel blade. Longitu-
dinal incisions were made perpendicular to its surface down to the
calciﬁed cartilage zone. The cartilage tissue between these two cuts
was excised by cutting along the calciﬁed cartilage zone. The tissue
was then weighed using a Mettler AT261 DeltaRange balance
accurate to 0.01 mg (Mettler-Toledo, Inc. Columbus, Ohio) and half
of the sample was analyzed for percent collagen type II, while the
other half was analyzed for DNA content, and GAG content.
Collagen typing
Quantitative collagen typing was performed using a published
technique for measuring the relative amount of type II collagen
with respect to type I collagen in tissue samples37. This technique
has been modiﬁed to permit the analysis of very small samples
(1e10 mg) without initial puriﬁcation of the collagen38. Samples
were weighed, and the collagen peptides were cleaved with 0.5 ml
5% cyanogen bromide (CNBr) in deaerated 88% formic acid. In
preparation for electrophoresis, the samples were dissolved in
a sample buffer containing 0.063 M TriseHCL, pH 8, 3.3% sodium
dodecyl sulfate (SDS), 10% glycerol, 5% 2-mercaptoethanol, 0.001%
bromophenol blue, at a concentration of 8 mg (wet weight) of
sample per microliter of sample buffer. A 1 ml volume of samplewas
loaded onto 20% gels, and SDS-polyacrylamide gel electrophoresis
was carried out using a Phast System (Pharmacia LKB, Uppsala,
Sweden). As a control, cartilage was harvested from the patellar
groove of the contralateral limb and analyzed in the same manner
as the repair tissue. These control samples were run alongside the
repair tissue samples and served as a standard to ensure that the
banding pattern for 100% type II collagen was accurately repre-
sented and could be located for each experimental sample. The gels
were stained with Coomassie blue and scanned on a laser densi-
tometer (Pharmacia LKB). The percentage of type II collagen with
Table I
Detailed breakdown of the histological scoring (modiﬁed O’Driscoll) results and comparison between the defect repairs in the untreated controls and TGF-b1-pretreatment
groups. The scores are the mean values from three blinded observers for the number of specimens receiving the designated score. Mean percentages of the total number of
samples receiving a speciﬁc score are shown in parentheses. Scoring categories that were signiﬁcantly different (P< 0.05) are marked with * and shown in bold
Possible score TGF-b1 pretreated Untreated control
(n¼ 9) (n¼ 9)
Original O’Driscoll histological score
Cellular morphology Hyaline articular cartilage 4 2.3 (26%) 2 (22%)
Incompletely differentiated mesenchyme 2 6.6 (73%) 6.3 (70%)
Fibrous tissue or bone 0 0 (0%) 0.6 (7%)
Safranin-O staining Normal or nearly normal 3 1.3 (14%) 1.6 (18%)
Moderate 2 4.6 (51%) 5.3 (59%)
Slight 1 3 (33%) 2 (22%)
None 0 0 (0%) 0 (0%)
Surface regularity Smooth and intact 3 5 (56%) 4 (44%)
Superﬁcial horizontal lamination 2 2 (22%) 1 (11%)
Fissures-25e100% of the thickness 1 2 (22%) 2.6 (29%)
Severe disruption, including ﬁbrillation 0 0 (0%) 1.3 (14%)
Structural integrity* (P¼ 0.0003) Normal 2 6 (66%) 3 (33%)
Slight disruption, including cysts 1 3 (33%) 2.6 (29%)
Severe disintegration 0 0 (0%) 3.6 (40%)
Thickness 100% of normal adjacent cartilage 2 9 (100%) 9 (100%)
50e100% of normal cartilage 1 0 (0%) 0 (0%)
0e50% of normal cartilage 0 0 (0%) 0 (0%)
Bonding to adjacent cartilage* (P¼ 0.0047) Bonded at both ends of graft 2 1.6 (18%) 1 (11%)
Bonded at one end, or partially at both ends 1 6.3 (70%) 4.6 (51%)
Not bonded 0 1 (11%) 3.3 (37%)
Hypocellularity* (P¼ 0.0015) Normal cellularity 3 4 (44%) 2.3 (26%)
Slight hypocellularity 2 3.3 (37%) 2 (22%)
Moderate hypocellularity 1 1.6 (18%) 3.6 (40%)
Severe hypocellularity 0 0 (0%) 1 (11%)
Chondrocyte clustering No clusters 2 1.6 (18%) 2.6 (29%)
<25% of the cells 1 5.3 (59%) 5 (56%)
25e100% of the cells 0 2 (22%) 1.3 (14%)
Freedom from degeneration of adjacent cartilage Normal cellularity, no clusters, normal staining 3 0.6 (7%) 2 (22%)
Normal cellularity, mild clusters, moderate staining 2 4.3 (48%) 4.6 (51%)
Mild or moderate hypocellularity, slight staining 1 3.6 (40%) 1.6 (18%)
Severe hypocellularity, poor or no staining 0 0.3 (3%) 0.6 (7%)
Scoring criteria for bone layer reconstruction
Subchondral bone alignment Level 2 0.3 (3%) 0 (0%)
Depressed 1 8.6 (97%) 9 (100%)
Elevated or none 0 0 (0%) 0 (0%)
Bone integration* (P¼ 0.0001) Integrated 2 3.6 (40%) 2 (22%)
Partially integrated 1 5 (56%) 4 (44%)
Not integrated 0 0.3 (3%) 3 (33%)
Bone inﬁltration into defect area* (P¼ 0.002) Nearly complete or complete 2 0.3 (3%) 0 (0%)
Partial 1 8 (89%) 4 (44%)
None or minimal 0 0.6 (7%) 5 (56%)
Tidemark continuity* (P¼ 0.0059) Present, no gaps 2 2.6 (29%) 0.3 (3%)
Present, with gaps 1 3.3 (37%) 2.6 (29%)
Absent 0 3 (33%) 6 (66%)
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the a1(II)CB10 to the a1(I)CB7, 8 and a1(II)CB11 peaks in each
lane37,38.DNA and GAG content
After being weighed, the cartilage tissue samples to be analyzed
for DNA and GAG content were digested in 1 ml of 50 mg/ml
proteinase K in 100 mM K2HPO4 (pH 8) at 60C for 16 h. The reac-
tion was stopped by placing the samples in a 90C water bath for
10 min. The resulting digest was used for both the DNA and GAG
assays. Double stranded DNA (dsDNA) content was determined
using Quant-iT PicoGreen dsDNA Kit (invitrogen Eugene, OR) witha Fluorostar Plate Reader (BMG Labtechnologies, Offenburg,
Germany). GAG content was determined using the dimethyl-
methylene blue assay (DMMB, Blyscan Sulfated Glycosamino-
glycan Assay Kit; Biocolor Ltd., NI, UK). GAG content was
normalized to dsDNA content. All samples were analyzed in
duplicate and their values averaged.Statistical analysis
In this study, the analysis outcomes included quantitative GAG
content, collagen typing, cartilage scoring, and mechanical prop-
erties of the newly formed repair tissue. The experimental factor
was treatment (TGF-b1 pretreated vs control periosteal grafts). The
A. Olivos-Meza et al. / Osteoarthritis and Cartilage 18 (2010) 1183e1191 1187datawere analyzed using 2-factor analysis of variance. All statistical
tests were two-sided and P-values less than 0.05 were considered
statistically signiﬁcant. Data are expressed as means with 95%
Conﬁdence Intervals (CIs).
Results
Gross observations
In order to minimize manipulation of the periosteal grafts
during surgery and duration of the procedure, precise measure-
ments of the size of the graft, and assessment of the mechanical
properties of the grafts were not taken. However, the following
general observations were made during the surgical procedure,
which are worth noting. Consistent with our previous study28, the
TGF-b1-pretreated periosteum was obviously thicker and easier to
elevate from the bone compared to control periosteum. Also, the
TGF-b1-pretreated periosteum did not appear to shrink after graft
harvest, while the untreated periosteum did shrink noticeably as
expected. In addition, the TGF-b1-pretreated periosteum was
ﬁrmer while retaining ﬂexibility and in general was easier to
handle than the control periosteum during the surgical procedure.
At 6-weeks post-op, contractures or intra-articular adhesions
were not observed in the joints. Complete ﬁlling of the defects with
regenerated tissue was observed in both surgical groups with
integration into the surrounding tissue and reformation of the
original contours of the patellar groove (Fig. 2). Also, the periosteal
graft harvest site was replaced with regenerated periosteum in
both the TGF-b1-pretreated and control groups.
Histological results
As illustrated in Fig. 2, neocartilage was formed in both the TGF-
b1-pretreatment and control groups. However, the structural
integrity, integration and bone regeneration in the repair tissue
appeared to be better in the TGF-b1-pretreated group [Fig. 2(B)]
compared to the control group [Fig. 2(A)]. These observations are
reﬂected in the histological scores (Fig. 3 and Table I). The score for
structural characteristics (Fig. 3), which includes scores for surface
regularity, structural integrity, thickness, and bonding to adjacent
cartilage, was signiﬁcantly higher (P¼ 0.0002) in the TGF-b1-pre-
treated group, 7.2 (6.4e8.0), compared to the untreated control, 5.6Fig. 2. Safranin O/fast green stained histological sections (AeC) and corresponding gross im
periosteum (B & E), and contralateral controls (C & F). The specimens are typical for each
regeneration in the TGF-b1-pretreatment group (B) compared to the untreated periosteum(4.8e6.3). As shown in Table I, 40% of the control samples were
scored as severely disintegrated compared to none in the TGF-b1-
pretreated group. The mean scores for the TGF-b1-pretreatment
group were also signiﬁcantly higher for structural integrity
(P¼ 0.0003), bonding to adjacent cartilage (P¼ 0.0047), and
hypocellularity (P¼ 0.0015).
The total bone histological score (Fig. 3) was also signiﬁcantly
higher (P¼ 0.003) in the TGF-b1-pretreatment group, 3.9 (3.3e4.5),
compared to untreated controls, 3.0 (2.4e3.7). Within the total
bone score, the TGF-b1-pretreatment group had signiﬁcantly
higher mean scores for integration (P< 0.0001), inﬁltration
(P¼ 0.002) and tidemark continuity (P¼ 0.0059).
The total histological scores (Fig. 3) were also signiﬁcantly
higher (P¼ 0.0001) in the TGF-b1-pretreatment group, 20.2
(19.0e21.4), compared to the control, 17.5 (16.3e18.7). Importantly,
all histological scores for both defect repair groups were signiﬁ-
cantly lower than the contralateral controls (Fig. 3). Overall, similar
results were observed when the histological samples were scored
using the ICRS scoring system (data not shown).
Biochemical and biomechanical results
As shown in Table II, no signiﬁcant difference in DNA content
was observed between the defect repair groups. However, the DNA
content in both the defect repair groups was signiﬁcantly higher
than the respective contralateral controls (P¼ 0.0002). Likewise, no
signiﬁcant difference in percent collagen type II was observed
between the defect repair groups (Table II). However, if pooled
(untreated plus TGF-b1-pretreatment groups), the percent collagen
type II in the defect repair groups was signiﬁcantly lower than the
contralateral controls (P¼ 0.0409). No signiﬁcant differences in
normalized GAG content were observed between any of the groups
(Table II).
While the mean equilibrium modulus of the cartilage for the
TGF-b1-pretreatment groups were higher than the controls, the
differences were not statistically signiﬁcant (Table II).
Cambium thickness in the regenerated periosteum
As shown in Fig. 4, 6 weeks after harvesting periosteal grafts for
transplantation, the cambium layer of the regenerated periosteum
in the TGF-b1-pretreatment group, 121 mm (94.1e148.5 mm), wasages (DeF) of defects repaired with untreated periosteum (A & D), TGF-b1-pretreated
group at 6-weeks post-op. Improvements in the structural characteristics and bone
group (A) are clearly visible.
Fig. 3. Higher magniﬁcation images of Safranin O/fast green stained histological sections of the articular surfaces (A and B) and the base of the defects (C and D) from osteochondral
defects repaired with untreated (A and C) and TGF-b1-pretreated periosteum (B and D) and histological scores at 6-weeks post-op. *Histological scores for cartilage structural
characteristics (P¼ 0.0002) and total bone (P¼ 0.003), and the total histological scores (P¼ 0.0001) for the TGF-b1-pretreatment group were signiﬁcantly higher than the untreated
control group based on post-hoc testing using least squares means differences Student’s t test. However, the scores for both of the defect repair groups were signiﬁcantly lower than
the contralateral controls. The scores are the mean values from three blinded observers. The data presented are means with 95% CI (n¼ 9).
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in the untreated control group, 74 mm (52.0e96.3 mm).
Discussion
This study demonstrates that in situ pretreatment of periosteum
with TGF-b1 improves the quality of osteochondral tissue regen-
erated from transplanted periosteum in vivo at 6-weeks post-op
compared to untreated periosteum in 12 month-old rabbits. These
ﬁndings support our previous in vitro results demonstrating that
subperiosteal injection of TGF-b1 increases the number of cambium
cells in the tissue and increases in vitro cartilage production from
periosteum explanted from adult rabbits28. This approach could
provide a simple and effective method to partially overcome the
age-related decline in the regenerative capacity of periosteum21e24.The main aspects of the regenerated tissue that showed
improvement with TGF-b1-pretreatment were the structural
characteristics of the cartilage and the bone regeneration. No
signiﬁcant differences were observed in the DNA content, percent
type II collagen, or GAG content between the defect repair groups.
Therefore, these biochemical parameters fail to explain the histo-
logical observations. We speculate that other components of the
cartilage matrix that were not measured in this experiment may be
differentially expressed leading to increased matrix organization
and the observed improvement in structural integrity found with
the TGF-b1-pretreated periosteum. Additional studies are needed
to address this issue. Also, no signiﬁcant increase in equilibrium
modulus of the neocartilage was observed with TGF-b1-pretreated
periosteum, although the means were higher. As expected, the
tissue regeneration process is incomplete at 6-weeks post-op, and
Table II
Quantitative analyses for DNA content, percent collagen type II, normalized GAG and equilibrium modulus in regenerated tissue from untreated or TGF-b1-pretreated
periosteum and contralateral controls at 6-weeks post-op. No signiﬁcant differences were detected between the defect repair groups. However, the DNA content in the defect
repair groups was signiﬁcantly higher than the contralateral controls (P¼ 0.0002), whereas, if pooled, the percent collagen type II was signiﬁcantly lower in the defect repair
groups (P¼ 0.0409) compared to the contralateral controls, based on post-hoc testing using least squares means differences Student’s t test. The data presented aremeans with
95% CI (n¼ 9 or 10).
Contralateral control Defect repair
Untreated TGF-b1 pretreated Untreated TGF-b1 pretreated
Biochemical and biomechanical analyses
DNA content (mg) 0.057 (0.033e0.081) 0.055 (0.030e0.079) 0.13 (0.084e0.17) 0.13 (0.085e0.17)
Collagen type II (%) 68.0 (46.7e89.3) 77.2 (50.5e103.8) 47.0 (26.6e67.4) 53.6 (32.1e75.1)
Normalized GAG content (mg GAG/mg DNA) 95.2 (42.7e147.7) 99.3 (46.9e151.8) 109.0 (62.4e155.5) 68.8 (19.8e118.0)
Equilibrium modulus (MPa) 0.30 (0.17e0.43) 0.53 (0e1.1) 0.44 (0e0.98) 0.65 (0.13e1.2)
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limbs. Additional studies are currently being conducted to examine
the outcome of this technique at 6 and 12 months post-op. These
forthcoming results may provide insight into the maturation and
durability of the regenerated tissue. It is also important to note that
although TGF-b1 was not injected into the joint, we cannot rule out
the possibility of a direct effect of TGF-b1 on the operated joint
through systemic circulation or diffusion into the joint.
Interestingly, the regenerated periosteum from the graft harvest
site in the TGF-b1-pretreatment group was signiﬁcantly thicker
than the control group at 6-weeks post-op. This observation
suggests that the effect produced by TGF-b1 injection 7 days prior
to surgery was prolonged at the graft donor site. This may be due to
stimulation of endogenous TGF-b expression in the surrounding
periosteum by the exogenous TGF-b1 as previously observed in
vitro39,40.
It is important to recognize that the post-operative care in this
study was normal cage activity, which is demonstrated to be infe-
rior to the use of continuous passive motion (CPM) for theFig. 4. Representative H & E stained histological sections of regenerated periosteum
from the untreated (A) and TGF-b1-pretreated (B) periosteal graft harvest sites 6 weeks
after graft harvest. The periosteal tissue was regenerated in both groups, however, the
cambium layer in the regenerated periosteum from the TGF-b1-pretreatment group
was signiﬁcantly thicker than the untreated group (P¼ 0.0065), based on post-hoc
testing using least squares means differences Student’s t test. The cambium layers are
between the yellow lines, with the bone on the bottom and the ﬁbrous layer on the top
in panels A & B. The data presented are means with 95% CI (n¼ 9 or 10).regeneration of osteochondral tissue by periosteal transplantation
in rabbits21,22,41. Therefore, it is conceivable that combining TGF-b1-
pretreatment with CPM post-operatively might produce an added
improvement in periosteal transplantation. At a minimum,
producing a periosteumwith a thicker cambium layer should make
harvesting a periosteal graft with viable cambium cells technically
easier as observed in this study. Previous studies have documented
the importance of procedure-speciﬁc training for successfully
harvesting chondrogenic periosteum35. Providing a thicker peri-
osteum that is easier to elevate and handle during transplantation
may improve the learning curve.
As summarized in Table I, the subchondral bone alignment was
below the level of the normal (surrounding) tissue in all samples
suggested a lack of mineralization into the normal cartilage layer at
this early time point. However, it has previously been documented
that endochondral ossiﬁcation of transplanted periosteal grafts can
extend beyond the normal subchondral bone, especially in the
absence of appropriate mechanical stimulation21,22,42. Because CPM
was not used on the rabbits in this experiment, it is possible that
mineralization beyond the normal subchondral bone will occur
over time.
Rejuvenated periosteal grafts could be suitable in the clinical
application for cartilage and bone repair not only because they
meet the three primary requirements for tissue engineering43 (i.e.,
provides a matrix, source of stem cells and growth factors) but also
because they can be harvested as a whole autologous tissue graft
with minimal morbidity at the donor site in the same surgical
procedure. In addition, no ex vivo culture step is required for the
pretreatment approach described in this study. The versatility of
periosteum is also a great asset. Periosteum can be used alone as
awhole tissue graft10e13, or the graft can be combinedwith another
biological or synthetic graft31,32,41,44,45.
Recent results also suggest that extracorporeal shockwaves
(ESW) may be used as a non-invasive method to increase the
number of cambium cells in periosteum46. However, whether
pretreatment with ESW results in improved regenerative capacity
of periosteum has not yet been reported. Such continued efforts to
better exploit the regenerative capacity of periosteum are worth-
while considering the advantages of autologous periosteal grafts
described above. Although the number of cambium cells is reduced
with age, they are still present and maintain multipotency, and the
ability to proliferate and respond to growth factors throughout
adult life47,48.
The in situ pretreatment approach described herein could be
considered a ‘second generation’ technique of periosteal trans-
plantation that offers improvement over conventional periosteal
transplantation. However, we recognize that this approach is only
one step towards achieving optimal, durable cartilage regeneration
and inclusion of other factors such as mechanical stimulation will
likely be needed to achieve this larger goal.
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